We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Analgesic Treatment Mediated by Arcoxia (0663-093)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00380523
First Posted: September 26, 2006
Last Update Posted: March 17, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
  Purpose
Allow physicians to test the efficacy of arcoxia in patients with acute pain.

Condition Intervention Phase
Pain Drug: MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Analgesic Treatment Mediated by Arcoxia

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Evaluate pain using the verbal analog scale (evaluate pain before starting treatment and then evaluate pain every day after had taken arcoxia up to three days)

Secondary Outcome Measures:
  • Patient satisfaction with the drug therapy using PGART scale
  • Patient satisfaction was obtained at the end of treatment(on third day)

Estimated Enrollment: 237
Study Start Date: April 2005
Study Completion Date: May 2005
Primary Completion Date: May 2005 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of acute pain susceptible of pharmacological treatment
  • Greater than 18 years of age
  • Voluntary acceptance to participate in the study and signature of the informed consent form

Exclusion Criteria:

  • Allergy to etoricoxib or any of its components
  • Less than 18 years old
  • Patient is taking anticoagulants
  • Patient that already has taken any drug as analgesic
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00380523


Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00380523     History of Changes
Other Study ID Numbers: 0663-093
2006_034
First Submitted: September 22, 2006
First Posted: September 26, 2006
Last Update Posted: March 17, 2015
Last Verified: March 2015

Additional relevant MeSH terms:
Analgesics
Etoricoxib
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Antirheumatic Agents